Positive results in first Chinese study with BioGaia’s drops in infants with colic

A Chinese study of infants with colic shows that babies given Lactobacillus
reuteri Protectis cry significantly less compared to babies given placebo.
The newly published study is the fifth positive colic study with Lactobacillus
reuteri Protectis and the results confirm the positive results of earlier
studies.
100 per cent treatment success
Treatment succes was observed in all infants supplemented by Lactobacillus
reuteri Protectis while it was seen in barely 16 per cent of the placebo group.
In addition, the study showed 100 per cent parent satisfaction in the
Lactobacillus reuteri Protectis group, while barely 16 percent among parents of
children in the placebo group reported treatment satisfacion. 42 infants were
included in the study.

The study was published online in Antonie van Leeuwenhoek 16 April 2015. More
information on colic (http://www.biogaia.com/sites/biogaia.com/files/Press
-material-BioGaia_131030.pdf), study
details (http://www.biogaia.com/sites/biogaia.com/files/Study-facts-Mi-and-Zhao
-April-2015.pdf) and previous colic studies with Lactobacillus reuteri
Protectis (http://www.biogaia.com/clinical
-studies?field_bg_indication_tid=182&age=All&author=All) is found through the
attached links.

"With this study – the fifth independent, positive study with Lactobacillus
reuteri Protectis on colic – we further strengthen our position in the
paediatric field. Furthermore, it is valuable that we now also have strong data
in this field from a study conducted in China”, says Peter Rothschild,
President, BioGaia.

Latest press releases from BioGaia
2015-04-08 Notice to attend the Annual General Meeting of BioGaia AB
2015-03-26 BioGaia subsidiary IBT starts trial already this year
2015-03-23 BioGaia signs exclusive agreement for oral health products in Mexico

BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 27 April 2015, 08:00
am CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com